The mitochondria are a membrane-bound cellular organelle commonly referred to as the “powerhouse” of the cell. Their main ...

US FDA approves AbbVie’s Decnupaz to treat adult patients with blastic plasmacytoid dendritic cell neoplasm: North Chicago Friday, May 29, 2026, 17:00 Hrs [IST] AbbVie announced ...

(Corrects to clarify the total number of patients in the study in paragraph 10) May 27 (Reuters) - The U.S. Food and Drug ...

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and ...

Complete remission rate of 69% in blastic plasmacytoid dendritic cell neoplasm ...

Scientists have developed a powerful new technique that allows them to observe how individual cells manufacture proteins ...

FDA approval covers adult BPDCN in both newly diagnosed and relapsed/refractory disease, leveraging breakthrough therapy, orphan drug designation, and priority review status. CADENZA enrolled 33 ...

DECNUPAZ is the first and only antibody-drug conjugate (ADC) approved for blastic plasmacytoid dendritic cell neoplasm (BPDCN) that is initiated in an outpatient ...

Cellectis doses first patient with BPDCN in phase I study of UCART123: New York Saturday, August 19, 2017, 18:00 Hrs [IST] Cellectis, a clinical-stage biopharmaceutical company fo ...

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration with Diakonos Oncology Corp., a clinical-stage biotechnology company ...

Solu Therapeutics, a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced that the U.S. Food and Drug ...

AbbVie’s ADC has secured FDA clearance for an ultra-rare blood cancer while the agency has delayed its decision on ...